Resources from the same session
1207O - Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
Presenter: Maria Carmela Piccirillo
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA44 - Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Presenter: Hirotsugu Kenmotsu
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA45 - Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Presenter: Bob Li
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA46 - Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
Presenter: Robin Cornelissen
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Natasha Leighl
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Invited Discussant LBA45 and LBA46
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Daniel Shao Weng Tan
Session: Proffered Paper session - NSCLC, metastatic 1
Resources:
Slides
Webcast